← Markets

Relmada Therapeutics, Inc.

RLMD · NASDAQ

Market closed$5.00$-0.240000 (-4.58%)After hours $4.71 · -5.80%

Key statistics

Previous close$5.00
Open$5.26
Day high$5.47
Day low$4.96
52-week high$8.00
52-week low$0.550000
Market cap524.45M
Volume2.53M
Average volume1.62M
P/E ratio-4.59
Forward P/E—
EPS-1.09
Dividend yield0.00%

Market context

Why it moved

RLMD (Relmada Therapeutics) declined today amid a lack of significant positive catalysts and broader selling pressure in small-cap biotech stocks, with no major company-specific news to support its valuation.

MarketbeatInstagramTiktokGoogleTiktok

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Relmada Therapeutics plunged sharply after announcing it would report Q2 2026 financial results on August 6, a routine update that appeared to reignite investor anxiety over the clinical-stage company's cash burn and lack of near-term catalysts. Despite Mizuho maintaining a Buy rating with a $19 price target just days earlier, the stock sold off heavily on above-average volume, with shares recovering slightly in after-hours trade. The broader healthcare sector (XLV) held relatively steady, suggesting the selloff was largely company-specific rather than sector-driven.

-12.0773

July 14, 2026Relmada Therapeutics edged modestly higher on above-average volume, even as broader markets declined amid renewed U.S.-Iran tensions that rattled equities and sent oil prices surging. The small-cap biotech is navigating a challenging sector backdrop — healthcare earnings are forecast to drop 9% in Q2, while biotech specifically faces a projected 79% earnings decline — though Goldman Sachs and Jim Cramer have both highlighted biotech as a prime M&A target, with neuroscience among the key areas where large-cap pharma is hunting for deals, a dynamic that could benefit clinical-stage names like Relmada.

0.624

July 11, 2026Relmada Therapeutics closed modestly lower, slipping about 1.5%, though shares rebounded over 2% in after-hours trading. The session came amid a broadly supportive backdrop for biotech—Jim Cramer flagged the sector as the market's hottest group, the XLV healthcare ETF approached record highs, and COMPASS Pathways' strong Phase 3 data in treatment-resistant depression lifted sentiment across CNS-focused names. Ongoing U.S.-Iran tensions and geopolitical uncertainty weighed on the broader market, though the S&P 500 managed a modest 0.42% gain, with investors rotating toward healthcare as a relative safe haven.

-1.5361

July 9, 2026Relmada Therapeutics closed little changed, but shares edged up 1.87% in after-hours trading amid a broader sector tailwind that saw healthcare outperform on the day. Biotech sentiment has been notably bullish, with Jim Cramer recently calling the group "the hottest in the market" and predicting an M&A wave as the regulatory environment under new FDA leadership becomes more favorable — dynamics that could benefit small-cap biotech names like Relmada. The broader market faced headwinds from Trump declaring the U.S.-Iran ceasefire "over," sparking an oil surge and risk-off move, yet healthcare and biotech showed resilience as capital rotated out of crowded semiconductor and AI hardware positions.
July 7, 2026Relmada Therapeutics edged higher in regular trading and extended the gain in after-hours, with the stock continuing to benefit from a powerful sector tailwind as biotech has emerged as the market's hottest group. Jim Cramer's bullish call on biotech M&A — citing a friendlier FDA environment and a wave of deals expected from cash-rich acquirers like Eli Lilly and Gilead — has lifted sentiment across small- and mid-cap biotech names, while the healthcare sector ETF (XLV) remains near its 52-week high following back-to-back weeks of market-leading performance.

1.2638

July 3, 2026Relmada Therapeutics closed down modestly, giving back some gains following its high-profile Russell 2000 and Russell 3000 index inclusion last week, which had driven a 4.33% rally on June 29. The index addition — effective June 26 — broadens the company's institutional investor base and validates its ~997% one-year stock appreciation, while H.C. Wainwright's Buy rating with a $12 price target and the advancing NDV-01 oncology program remain key investor focal points. The broader healthcare sector (XLV) held near 52-week highs, providing a constructive backdrop even as Relmada pulled back slightly after its recent run.

-1.7214

July 2, 2026Relmada Therapeutics tumbled nearly 8% in regular trading, giving back gains that followed its recent addition to multiple Russell indexes. The stock added to the Russell 2000, Russell 3000, Russell Microcap, and several growth benchmarks effective June 26 — a milestone that CEO Sergio Traversa called a reflection of Relmada's ongoing progress and that drove a 4.33% gain on June 29. Despite the index-driven institutional visibility boost and H.C. Wainwright's Buy rating with a $12 price target (implying ~83% upside from prior close), profit-taking and broader market pressure on growth biotech names weighed on shares today, with the healthcare sector ETF (XLV) holding essentially flat.

-7.659

June 30, 2026Relmada Therapeutics gained over 4% after announcing its inclusion in the Russell 2000 and Russell 3000 indexes, effective June 26, following the annual Russell reconstitution. The index additions — which also include the Russell Microcap and Russell 3000E indexes — are expected to drive mandatory buying from passive funds that track these benchmarks, boosting institutional visibility. The move builds on recent momentum from H.C. Wainwright's Buy initiation with a $12 price target and Piper Sandler's Overweight rating, with the six-analyst consensus target near $12.67 — roughly 81% above the current close — reflecting Street optimism around NDV-01, its next-gen intravesical bladder cancer therapy.

4.3348

Moomoo · July 10, 2026Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $19Stock Titan · June 29, 2026Relmada lands in Russell 2000 and Russell 3000 after reconstitutionPluang · June 29, 2026Relmada Therapeutics joins Russell 2000 and 300...Investing.com · June 23, 2026Relmada Therapeutics stock maintained at Buy by H.C. WainwrightInvesting.com · June 11, 2026Relmada appoints Michael Quirk as senior advisor for sepranoloneTradingView · May 13, 2026Relmada Therapeutics Q1 Earnings Call HighlightsSimply Wall Street · March 10, 2026A Look At Relmada Therapeutics (RLMD) Valuation After NDV‑01 Phase 2 Bladder Cancer DataStocktwits · March 9, 2026RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors
Mt Newswire · June 29, 2026Relmada Therapeutics Joins Russell 2000, Russell 3000 Indexes
Benzinga · June 29, 2026Relmada Therapeutics Joins Russell 2000 Index And The Russell 3000 Index Effective
Mt Newswire · June 18, 2026HC Wainwright Initiates Relmada Therapeutics at Buy With $12 Price Target
Benzinga · May 28, 2026Relmada Therapeutics Increases Authorized Common Stock From 150M To 200M Shares Following Shareholder Approval
Benzinga · May 13, 2026Relmada Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed
Mt Newswire · May 12, 2026Relmada Therapeutics Q1 Loss per Share Narrows
Mt Newswire · May 12, 2026Earnings Flash (RLMD) Relmada Therapeutics Posts Q1 Loss $0.22, vs. FactSet Est of $0.20 Loss
Benzinga · May 12, 2026Relmada Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate

Peers

S&P 500SPX · $7,443.28-0.19%Axsome Therapeutics, Inc.AXSM · $228.49-0.66%COMPASS Pathways plcCMPS · $11.78-4.62%Cybin Inc.CYBN.NE · 10.10-1.27%uniQure N.V.QURE · $40.00-0.62%MBX Biosciences, Inc. Common StockMBX · $60.12-4.45%SELLAS Life Sciences Group, Inc.SLS · $12.59-4.58%Immunome, Inc.IMNM · $22.50+0.81%Cingulate Inc.CING · $4.56+0.44%Corcept Therapeutics IncorporatedCORT · $91.63+1.23%Neumora Therapeutics, Inc. Common StockNMRA · $1.63+1.24%